Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liyuan Tao has a total of 427 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global Trends And Inequalities In Life Expectancy, Healthy Life Expectancy, And Morbidity Gaps At Age 60 Across 185 Countries And Areas From 2000 To 2023

    by Shaojie Li, Longbing Ren, Mingzheng Hu, Miaomiao Lin, Kaixuan Tang, Liyuan Tao, Yi-Da Tang

    Background: Population ageing has shifted the global health agenda from extending survival alone towards ensuring that additional years of life are lived in good health. Although life expectancy and healthy life expectancy at birth have been extensively studied, less is known about whether gains in survival after age 60 have been accompanied by equivalent gains in healthy survival and how these patterns differ across countries, socioeconomic development levels, and sexes. We assessed global trends and inequalities in life expectancy, healthy life expectancy, and morbidity gaps at age 60 from 2000 to 2023.Methods: We analyzed annual estimates of life expectancy (LE60) and healthy life expectancy (HALE60) for 185 countries from the WHO Global Health Observatory. We calculated absolute morbidity gaps as LE60 minus HALE60 and proportional gaps as a percentage of LE60. We assessed national morbidity transitions, decomposed changes in LE60 by age and changes in morbidity gaps by longevity and morbidity share, examined cross-national convergence, and quantified socioeconomic inequalities using the Slope Index of Inequality (SII) and Relative Index of Inequality based on Socio-demographic Index rankings. We also assessed sex differences and estimated cause-specific allocations of morbidity gap years using disability burden.Findings: Globally, LE60 increased from 19.2 years (95% UI 18.6–19.9) in 2000 to 21.2 years (19.8–22.7) in 2023, whereas HALE60 increased from 14.3 years (12.6–15.9) to 15.7 years (13.3–18.0). The absolute morbidity gap widened from 4.9 to 5.5 years, while the proportional gap increased slightly from 25.5% to 25.9%. Of the 0.60-year increase in the absolute gap, 85.8% was associated arithmetically with longer survival. Both gaps increased in 132 (71.4%) of 185 countries, whereas 39 (21.1%) had a widening absolute gap but a declining proportional gap. Between-country differences widened, with no evidence of β convergence, indicating no overall catch-up in LE60 or HALE60. The Slope Index of Inequality increased for LE60, HALE60, and the absolute morbidity gap, indicating widening absolute socioeconomic disparities, whereas relative inequalities changed less. Between 2019 and 2023, LE60 and HALE60 declined by 0.2 and 0.1 years, respectively, with mortality changes at ages 80 years or older contributing negatively to LE60. In 2023, females lived 3.2 years longer than males but had a 1.3-year larger morbidity gap. Musculoskeletal diseases accounted for the largest share of the morbidity gap in both sexes.Interpretation: Gains in LE60 exceeded those in HALE60, widening the absolute morbidity gap in most countries, although changes in the proportional gap varied. The absence of overall β convergence and widening absolute socioeconomic inequalities indicate that gains in healthy survival were not accompanied by narrowing cross-country disparities. Females lived longer than males but experienced larger morbidity gaps. Jointly monitoring absolute and proportional morbidity gaps, alongside LE60 and HALE60, may provide a more informative assessment of progress towards equitable healthy ageing.

  • Open Access

    Are study design characteristics in single-arm trials comparable with those of their objective performance criteria or performance goals? A scoping review

    by Handong Wang, Qianyun Chai, Fanhui Jin, Yuting Feng, Rui Cao, Zhihan Liu, Xiang Li, Minjing Luo, Liyuan Tao, Yutong Fei

    Objectives: Single-arm trials (SATs) with objective performance criteria (OPCs) or performance goals (PGs) are increasingly used for regulatory approval of medical devices and other interventions. However, the comparability of study design characteristics between SAT and their external comparator sources remains unclear. This scoping review aimed to evaluate the comparability of study design characteristics between SATs and their matched OPC/PG sources. Design: Scoping review. Data sources: PubMed, Embase, the Cochrane Library and four Chinese databases—China National Knowledge Infrastructure, Wanfang Data, CQVIP and SinoMed—were searched from inception to 30 April 2026. Eligibility criteria: We included SATs that used one or more OPCs or PGs as external comparators to evaluate safety and/or effectiveness endpoints and reported specific numerical values of OPCs or PGs. Data extraction and synthesis: Two reviewers independently screened the retrieved records and extracted data using a standardised form. For each included SAT, we retrieved the cited OPC/PG sources and extracted study design characteristics data (age, sex, health conditions, outcome definitions and measurement time points) for comparison. Age and sex were compared using summary t-tests and χ² tests; health conditions were assessed by two clinicians based on eligibility criteria and baseline characteristics. Results were stratified by OPC versus PG. Results: A total of 1243 records were identified, and 133 SATs were included. Most studies used PGs (84, 63.2%); 34 (25.6%) claimed to use OPCs, and 15 (11.3%) could not be classified. Of the 60 age comparisons available from 41 studies, 30 showed statistically significant differences; of the 82 sex comparisons available from 59 studies, 60 showed significant differences. Health conditions, outcome definitions and time points were assessed descriptively in a subset of studies, and discrepancies were also observed. Conclusion: Suboptimal comparability of study design characteristics was observed between SATs and their OPC/PG sources, which might influence the treatment effect estimates. Greater attention to the comparability of study design characteristics in SATs with OPC/PGs may improve the validity of evidence.

  • Open Access

    Attitudes, perceptions, and UTAUT-based factors influencing the acceptance of medical artificial intelligence among Chinese oncology healthcare professionals: a national cross-sectional survey

    by Zhaoyu Wang, Qianqian Dai, Maoshu Yang, Shiwu Shi, Jiaojiao Liao, Zhaoji Li, Xiaoqiu Dai, Liyuan Tao

    Objectives: To conduct a nationwide survey among professionals working in oncology departments in China to investigate their attitudes, perceptions, and experiences regarding medical artificial intelligence (AI), and to explore and compare the factors influencing AI behavioral intention (BI; willingness to adopt AI) between physicians and nurses using the Unified Theory of Acceptance and Use of Technology (UTAUT). Materials and Methods: A nationwide cross-sectional survey was conducted among professionals in oncology departments across China. Sociodemographic characteristics, awareness, perceptions, and user experiences related to medical AI were collected. The UTAUT was specifically applied to the third section of the survey to evaluate participants’ perceptions. Based on this framework, structural equation modeling (SEM) was performed to examine associations between BI and 6 latent constructs: performance expectancy (PE), effort expectancy (EE), social influence (SI), facilitating conditions (FC), perceived risk (PR), and trust (TR) based on the UTAUT. Subgroup SEM analyses were then conducted for physicians and nurses. Results: Six hundred ten valid responses were included in the final analysis, consisting of 188 (30.8%) physicians and 422 (69.2%) nurses. Only 17.7% reported having both heard of and used medical AI, while 67.7% had heard of it but never used it. SEM results showed that TR (confidence in system reliability; β = .668, P < .001) had the strongest effect on BI, followed by effort EE (perceived ease of use; β = .155, P = .026). Subgroup analyses revealed that for physicians, both EE (β = .257, P = .038) and TR (β = .486, P < .001) significantly influenced BI, while among nurses, only TR (β = .729, P < .001) showed a significant effect. Conclusions: There is a significant “awareness-usage gap” among Chinese oncology professionals, with high awareness but low practical integration of medical AI. This nationwide study indicates that TR and EE are associated with the intention to use AI. To bridge this gap, hospital management should implement differentiated training and local validation protocols that address the unique technical and ethical concerns of physicians and nurses, respectively.


  • Open Access

    Health Insurance Schemes and Chronic Disease Management Behaviours in China: Evidence from Women with Non-Communicable Diseases

    by Wenwen Liu, Liangyu Kang, Wenxin Yan, Chenyu Yan, Tianran Wang, Ning Zhang, Victor Yu Cui, Siyu Liu, Liyuan Tao, Min Liu, et al.

    Women in China bear a disproportionate burden of non-communicable diseases (NCDs), but limited evidence is available on whether different health insurance schemes are associated with chronic disease management behaviours. To examine the association between insurance type and chronic disease management behaviors among insured Chinese women with NCDs. We used data from a national cross-sectional online survey of approximately 7,000 women conducted in 31 provinces in China from 1 June to 20 August 2025 by the Institute for Health China Studies, Tsinghua University. Linear probability models with robust standard errors were used to estimate the associations between insurance type and three chronic disease management behaviours: medication adherence, lifestyle intervention, and health surveillance. Dietary regularity and health-product purchases were examined as spillover outcomes. Among survey respondents, 1,101 insured women aged 17–70 years reported at least one physician-diagnosed NCD. Compared with Urban Employee Basic Medical Insurance (UEBMI) enrollees, women covered by the government-funded medical subsidy program (GovMed) had a higher probability of medication adherence (β = 0.116, 95% CI: −0.003 to 0.236), whereas Urban–Rural Resident Basic Medical Insurance (URRMI) enrollees did not differ significantly (β = −0.026, 95% CI: −0.101 to 0.049). After adjustment, differences across schemes in lifestyle intervention and health surveillance were small and not statistically significant. Menopausal heterogeneity was concentrated in medication adherence: among post-menopausal women, GovMed enrollees had a 36.4-percentage-point higher probability of medication adherence than UEBMI enrollees (β = 0.364, 95% CI: 0.219 to 0.509). Supplementary commercial insurance was positively associated with health surveillance, but not with medication adherence or lifestyle intervention. Insurance-related differences in dietary regularity were weak and not statistically robust. Insurance-related differences in chronic disease management among Chinese women with NCDs are most evident for medication adherence, particularly among post-menopausal women. Broader self-management behaviours appear less responsive to scheme differences.


  • Accelerated biological aging is associated with faster multimorbidity progression: a UK biobank study

    by Zhaoyu Wang, Jiaojiao Liao, Dongwei Fan, Minyue Pei, Zhaoji Li, Qianqian Dai, Hui Wang, Nan Li, Liyuan Tao

    This study examined the associations of biological age accelerations (BAAs)-KDM-BA acceleration (via Klemera and Doubal's method) and PhenoAge acceleration (epigenetics-based), defined as residuals from regressing each biological age estimate on chronological age (CA)-with multimorbidity progression (measured by the Charlson Comorbidity Index, CCI), compared to CA. Utilizing UK Biobank data (n = 317,835; median follow-up: 13 years), Cox regression models adjusted for sex, ethnicity, lifestyle, and socioeconomic factors showed that each 1-year increase in KDM-BA acceleration raised the risk of CCI progression by 9.9% (HR [95% CI]: 1.099 [1.094-1.104]) and in PhenoAge acceleration by 4.3% (HR [95% CI]: 1.043 [1.041-1.044]). Consistent results were found in subgroup, sensitivity, and restricted cubic spline analyses, with PhenoAge acceleration achieving the highest predictive performance (C-index = 0.6755) compared to KDM-BA acceleration (0.6734) and CA (0.6701). These findings support the use of BAAs as cost-effective tools for assessing the risk of multimorbidity progression.


  • Open Access

    Rehabilitation status and preference for medical choice behaviours of long COVID-19 in China: a national cross-sectional study and discrete choice experiment

    by Jie Deng, Liyuan Tao, Nan Liu, Jun Li, Chenyuan Qin, Wenxin Yan, Yaping Wang, Min Du, Qiao Liu, Jue Liu

    Long COVID-19 has emerged as a growing global public health challenge requiring patient-centred responses, yet its prevalence and management are often underestimated. We aimed to investigate the rehabilitation status and medical choice behaviours among patients with long COVID-19 in China during the Omicron wave. We conducted a national cross-sectional study and a discrete choice experiment (DCE) in China from 4 July to 11 August 2023. We used the modified COVID-19 Yorkshire Rehabilitation Scale (C19-YRSm) to assess rehabilitation status. We collected preferences for medical choice behaviours of long COVID-19, demographics, health-related factors, and COVID-19 history. We assessed preferences for medical choice behaviours among people with long COVID-19 using mixed logit models. Among 2942 participants health status was significantly poorer than before COVID-19 infection. The prevalence of common symptoms assessed by C19-YRSm ranged from 21.52% to 72.67%, with fatigue (72.67%) being the most common, followed by breathlessness on walking up a flight of stairs (64.96%) and sleep problems (62.95%). Of these symptoms, the majority of participants (15.06-47.65%) reported mild problems. Of the five functional limitations, difficulty with other activities of daily living (31.03%) was the most common, followed by difficulty with communication (28.04%), while difficulty with personal care (9.65%) was the least common. The DCE results showed that the strongest attribute affecting preferences was medical distance (β = -1.135). While seeking healthcare for long COVID-19, people preferred lower out-of-pocket costs, a closer distance, a higher hospital level, nutritional supportive therapies or rehabilitation training, and medical services that integrate traditional Chinese and Western medicine. A substantial proportion of individuals developed long COVID-19 symptoms and functional limitations, most of which were mild. These findings highlight the importance of ongoing screening and comprehensive, tailored rehabilitation services to promote recovery and avert a public health crisis of long COVID-19.

  • Open Access

    Insulin Resistance and Blood Pressure Control on Cognitive Outcomes

    by Chenyu Fan, Xuan Wang, Liyuan Tao, Yundan Liao, Ling Jin, Quanyou Shi, Hu Wang, Yidan Shi, Tianqi Chang, Yuzhou Xue, et al.

    BACKGROUND: The influence of IR (insulin resistance) on the response of patients with hypertension to intensive systolic blood pressure treatment in terms of cognitive performance remains unclear, as does which circulating metabolites mediate this process. METHODS: This study comprised a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial). The SPRINT study enrolled 9361 participants aged ≥50 years with hypertension, of whom 7427 were analyzed. SPRINT participants were assigned to either intensive (9.07, lowering blood pressure to <120 mm Hg reduced dementia incidence more than standard control, hinting TyG modifies treatment effects, possibly via glycosyl ceramide. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01206062.


  • Open Access

    Stakeholder perception of quality management of investigator-initiated clinical trials

    by Wenqiang Li, Kailibinuer Ailimu, Nanxi Jia, Hongling Chu, Yiming Zhao, Liyuan Tao, Siyan Zhan, Lin Zeng

    Investigator-initiated clinical trials have flourished in China. However, research on stakeholders’ perceptions and management capacity of investigat

  • Open Access

    Planetary health diet benefits brain health by decelerating biological aging

    by Xi Li, Zhaoyu Wang, Gram Lu, Hongguang Chen, Yi Yang, Jue Liu, Liyuan Tao


  • Open Access

    Comparative Effects of Minodronate and Alendronate on Low Back Pain in Postmenopausal Osteoporosis and Age Influence: A Head-to-Head, Randomized Clinical Trial

    by Huan Wang, Hao Liu, Jie Huang, Xiuli Meng, Wei Wang, Wenhua Xiao, Dongyang Liu, Liyuan Tao, Chunli Song

    Purpose: This study aimed to compare the analgesic efficacy of minodronate versus alendronate for postmenopausal osteoporosis-related low back pain and evaluate age-dependent treatment responses. Methods: In this prospective, open-label randomized controlled trial, 72 postmenopausal women with osteoporosis were stratified by age (≥ 75 vs < 75 years) and allocated to 24-week treatment with daily minodronate (1 mg) or alendronate (10 mg). The primary endpoint was Visual Analogue Scale score changes from baseline to week 12. Secondary outcomes included age-stratified changes in lumbar spine and hip bone mineral density, along with serum bone turnover markers across different age groups (≥ 75 vs < 75 years). Results: Both regimens demonstrated comparable analgesic efficacy, with significant within-group Visual Analogue Scale reductions (minodronate: 11.08± 1.52%; alendronate: 9.86± 1.29%; P< 0.01 for both) but no between-group difference (P=0.237). At week 24, comparable lumbar bone mineral density improvements were observed (minodronate: 2.42%, 95% CI 1.8– 3.1; alendronate: 4.84%, 95% CI 3.9– 5.7; P=0.103). Marked bone turnover markers suppression persisted in both arms (CTX: 46.14% vs 41.25%; P1NP: 44.82% vs 44.11%). Age-stratified analyses revealed comparable therapeutic responses across subgroups (P> 0.05). Safety profiles were similar, with adverse event rates of 29.7% (minodronate) versus 43.2% (alendronate) (P=0.10), predominantly mild upper gastrointestinal symptoms. Conclusion: Both bisphosphonates demonstrated equivalent analgesic efficacy and comparable bone mineral density and biochemical effects, with age-independent responses. Safety profiles were similar, supporting clinical selection based on dosing convenience and gastrointestinal tolerance. Trial Registration: ClinicalTrials.gov number: NCT05673980 (08/12/2022). Plain Language Summary: This open-label trial demonstrated that minodronate and alendronate achieved comparable pain relief, bone mineral density improvement, and bone turnover markers suppression over 24 weeks, with similar safety profiles and age-independent efficacy. These findings support their equivalent analgesic and bone effects, guiding clinical selection based on dosing convenience and gastrointestinal tolerance.